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A b s t r a c t
Introduction: Optimal management of severe carotid in-stent restenosis remains unknown. Prevalence and risk factors of first 
and recurrent carotid in-stent restenosis in the multi-stent approach have not been established yet.
Aim: To evaluate the safety of different methods of endovascular treatment of carotid in-stent restenosis/recurrent restenosis 
and to establish its rate and risk factors.
Material and methods: Between January 2001 and June 2016, 2637 neuroprotected carotid artery stenting (CAS) procedures 
were performed in 2443 patients (men: 67.0%; mean age: 67.9 ±8.8 years, symptomatic: 45.5%). Doppler ultrasound (DUS) eval-
uation was performed at discharge, after 3–6 months, 12 months, and then annually. Peak systolic velocity of 2–3 and > 3.0 m/s 
as well as end diastolic velocity of 0.5–0.9 and > 0.9 m/s were DUS criteria for 50–69% and ≥ 70% carotid in-stent restenosis (ISR) 
respectively. For angiographically confirmed ≥ 70% stenosis balloon re-angioplasty was first line treatment.
Results: Out of 95 DUS detected > 50% ISR (95/2637; 3.6%), 53 were confirmed in angiography as ≥ 70% (53/2637; 2.0%, one 
total occlusion). All patients were treated with bare balloon (n = 19), drug-eluting balloon (n = 27) or stent-supported (n = 6) an-
gioplasty. One procedure was complicated with stroke (1.9%). Angiographic diameter stenosis (DS) was reduced from 83 ±8.3% to 
13 ±7.6% (p < 0.001). There were 13 cases of ≥ 70% recurrent ISR. Bilateral and high-grade stenosis were independent risk factors 
of restenosis. Initial Carotid Wallstent implantation was a risk factor of first and recurrent in-stent restenosis.
Conclusions: Endovascular treatment of carotid in-stent restenosis is safe. Bilateral and high-grade carotid artery stenosis may 
increase the risk of restenosis. Initial Carotid Wallstent implantation may increase the risk of first and recurrent restenosis.
Key words: risk factors, carotid artery, carotid artery stenting, in-stent restenosis, Carotid Wallstent.
S u m m a r y
Long-term durability of carotid artery stenting in terms of incidence of recurrent restenosis is a poorly examined issue. 
Our results suggest that the risk of restenosis is strongly associated with bilateral and high-grade carotid artery stenosis 
as well as with initial Carotid Wallstent implantation. These findings may influence the procedure strategy in patients with 
carotid artery stenosis.
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Introduction
Carotid artery stenting (CAS) has emerged as a strong 
alternative to carotid endarterectomy (CEA) in patients 
with carotid artery stenosis. Fast development of endo-
vascular techniques and increasing operators’ experi-
ence have resulted in significant reduction of the peripro-
cedural complication rate during CAS [1]. On the other 
hand, the growing number of CAS procedures performed 
around the world entails enlarging population of patients 
with in-stent restenosis (ISR) defined as reoccurrence of 
stenosis within stent. The prevalence of ISR after CAS 
ranges from 4.6% to 6.3%, with half of cases occurring 
within the first 6 months [2]. There are many ISR risk fac-
tors established; they include history of prior ipsilateral 
neck surgery or irradiation (‘hostile-neck’ lesions), diabe-
tes, female sex, and dyslipidemia [3–5]. Interestingly, the 
brand of stent has not yet been investigated as a poten-
tial risk factor. Although ISR accompanies endovascular 
carotid stenosis treatment from the very beginning, there 
are no well-defined guidelines on how to deal with this 
issue. Both conservative and interventional approaches 
have their supporters. Although ISR is usually asymptom-
atic, Donas et al. showed that ISR may be associated with 
thrombus formation and increased risk of thrombovascu-
lar events [6].
Moreover, 2-year follow-up in CREST revealed that pa-
tients who had restenosis within 2 years were at greater 
risk for ipsilateral stroke after the periprocedural period 
than were those who did not have restenosis [7].
The endovascular approach to ISR includes balloon 
angioplasty alone, cutting-balloon angioplasty, drug-elut-
ing balloon angioplasty, bare-metal and drug-eluting 
stent angioplasty [8–11]. Long-term durability of carotid 
artery stenting in terms of incidence of recurrent rest-
enosis is an even less examined issue. The therapeutic 
approach to first restenosis may influence both the im-
mediate result and further restenosis reoccurrence.
Aim
The aim of the study was to evaluate the safety of 
different methods of endovascular treatment of carotid 




Between January 2001 and June 2016, 2637 neuro-
protected carotid artery stenting procedures were per-
formed in 2443 patients (men: 67.0%; mean age: 67.9 
±8.8 years, range: 33–90, symptomatic: 45.5%), accord-
ing to the ‘tailored-CAS’ algorithm [12]. Patient charac-
teristics are shown in Table I. 
Ultrasound evaluation
Neurological and Doppler ultrasound evaluation 
(DUS) were performed at discharge, 3–6, 12 months after 
the procedure, and then annually. All DUS examinations 
were performed in a  certified laboratory using a  linear 
7–10 MHz probe to evaluate the degree of ISR and they 
were evaluated according to international standards. 
Restenosis was defined as ≥ 50% diameter reducing 
stenosis (or occlusion). The peak systolic velocity (PSV) 
criteria used to evaluate the degree of ISR were 170–
299 cm/s for 50–69% stenosis and > 300 cm/s for ≥ 70% 
ISR. PSV was measured within, distally and proximally to 
the stent. The highest PSV values were included in the 
analysis [13, 14]. The minimal time of observation was 
12 months.
Endovascular approach
Balloon (non-covered until 2012, drug covered after-
wards) angioplasty alone was performed in patients with 
angiographically confirmed ≥ 70% ISR. The balloon di-
ameter corresponded to the distal internal carotid artery 
(ICA) reference. For diffused restenosis, extending out-
side the stent, implantation of another stent was consid-
ered. Subsequent, recurrent ≥ 70% ISR was treated with 
Table I. Characteristics of 2443 patients undergo-
ing 2637 tailored CAS procedures
Parameter Value
Age, mean ± SD (range) [years]: 67.9 ±8.8 (33–90)
> 75 261 (16.8%)
Men 1685 (67.0%)
Smoking – current or past 1108 (44.1%)
Symptomatic ICA/CCA stenosis 1145 (45.5%)
Ipsilateral stroke* 982 (39.1%)
TIA* 512 (20.4%)
Peripheral artery disease 464 (18.4%)
Diabetes mellitus 783 (31.1%)
Insulin therapy (% of diabetics) 281 (35.9%)
Arterial hypertension 2339 (93.0%)
Hyperlipidemia 1681 (66.8%)
Significant bilateral ICA disease 817 (32.5%)
Contralateral ICA occlusion 334 (13.3%)
CAD by angiography‡ 1678 (66.7%)
ICA % stenosis by angiography, 
mean ± SD (range)
83.7 ±10 (52–99)
Continuous data are presented as means ± standard deviation; categorical data 
are given as counts (percentages). CAS – carotid artery stenting, ICA – internal 
carotid artery, CCA – common carotid artery, TIA – transient ischemic attack, 
CEA – carotid endarterectomy, CAD – coronary artery disease. *Within 6 months 
prior to CAS. ‡Coronary artery lesion(s) ≥ 50% by quantitative angiography.
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drug-eluting balloon (DEB), coronary drug-eluting stent 
(DES) implantation or self-expanding paclitaxel covered 
coronary stent supported angioplasty. The study flow 
chart is shown in Figure 1.
Definitions
–  Closed-cell design stent – characterized by intercon-
nected stent struts with small free cell areas (< 5 mm2),
–  Distal neuroprotection – filter system used for captur-
ing embolic material during carotid artery stenting with 
maintained ICA antegrade blood flow,
–  Intolerance – cerebral ischemia symptoms occurring as 
a  result of ICA flow blockage during neuroprotection/
angioplasty balloon inflation,
–  Neuroprotected carotid artery stenting – stent-support-
ed carotid artery angioplasty using distal or proximal 
neuroprotection system,
–  Proximal neuroprotection – system providing ICA blood 
flow cessation/reversal by common carotid and exter-
nal carotid balloon occlusion during CAS,
–  Restenosis – ≥ 50% diameter reducing in-stent stenosis 
(or occlusion) evaluated in ultrasound examination,
–  Symptomatic patient – with history of ischemic stroke/
transient ischemic attack (TIA), within preceding 6 months,
–  ‘Tailored-CAS’ – patient and lesion adjusted selection 
of neuroprotection system and stent type; preferential 
use of proximal neuroprotection and close-cell stent for 
high-risk lesions (> 95% stenosis, thrombus-containing 
lesions, ’soft’ lesions, i.e. with computed tomography 
density of < 60 HU) and in symptomatic patients.
Ethics
This study was approved by the Committee on Re-
search Ethics at our hospital, in compliance with the eth-
ical guidelines of the Declaration of Helsinki. All partici-
pants gave written informed consent prior to study entry.
Statistical analysis
Continuous data were presented as means ± stan-
dard deviation; categorical data were given as counts 
(percentages). Normality of distribution was assessed 
by Kolmogorov-Smirnov test. The c2 test was used for 
comparison of categorical data. Potential risk factors in-
cluded sex, age, smoking status, hypertension, hypercho-
lesterolemia, prior stroke/TIA, prior ipsilateral CEA, con-
tralateral stenosis/occlusion, stenosis grade, peripheral 
artery disease, stent type (open- vs. closed-cell design), 
stent brand and stent underexpansion defined as post-
CAS stenosis of > 30%. In the case of repeated angio-
plasty due to restenosis, follow-up procedures were then 
conducted the same way as after initial angioplasty.
Univariate and multivariate Cox proportional hazard 
regression models were used to determine risk factors 
for the development of the first and recurrent restenosis. 
For each potential risk factor, the hazard ratio and asso-
ciated 95% confidence interval from univariate analysis 
was examined. Multivariate analysis was then conducted 
with a logistic regression model. A p-value of < 0.05 was 
considered as statistically significant. All analyses were 
evaluated in Statistica 9.0 (StatSoft Inc).
Results
Demographic and clinical data
Out of 2637 stented arteries, in 95 cases (95/2637; 
3.6%) > 50% ISR restenosis was detected in DUS. Of 
those, 53 (53/2637; 2.0%) patients had ≥ 70% restenosis 
confirmed in angiography, including one case of asymp-
tomatic total occlusion. No stent fracture was detected. 
Mean PSV was 221 ±41 cm/s and 427 ±87 cm/s for 50–
69% and ≥ 70% restenosis respectively (p < 0.001). All 
52 patients (age: 49–77 years, 37 men, 19 patients symp-
tomatic before initial CAS, time from initial CAS to first 
restenosis mean 22 ±27 months, 56% cases within first 
year, 22% within second year) were treated successfully 
by the endovascular approach.
Angiographic data
ISR treatment included bare (n = 19), DEB (n = 27) or 
DES supported (n = 6, all for diffused restenosis) angio-
plasty. In 7 cases cutting-balloon use was necessary, as 
the standard balloon was slipping out of the stent. In the 
DEB group there were 11 (11/27; 41%) cases of intoler-
ance (cerebral ischemia) requiring shortening of inflation 
to < 40 s. The success rate was 100%; however, in 2 pa-
tients we were not able to cross a stent with distal em-
bolic protection device (EPD) while proximal EPD was not 
Figure 1. Study flowchart: detection and treatment of carotid in-stent restenosis
Initial CAS
No restenosis Restenosis 50–70%
> 70% restenosis  
in DUS
DUS evaluation  
at 3–6 months,  
12 months then 
annually
Angiographically 
confirmed > 70% 
restenosis
Further DUS evalua-
tion based on initial 
velocities rise
Balloon angioplasty, 
DEB angioplasty,  
DES supported  
angioplasty, self 




Łukasz Tekieli et al. Treatment of recurrent in-stent carotid restenosis
468 Advances in Interventional Cardiology 2019; 15, 4 (58)
used due to the risk of system intolerance. Angioplasty 
in those two cases was then non-protected. One (1.9%) 
procedure performed with distal EPD was complicated 
with ipsilateral ischemic stroke that occurred just after 
procedure completion. Angiographic diameter stenosis 
(DS) was reduced from 83 ±8.3% to 13 ±7.6% (p < 0.001). 
Characteristics of stents used for initial angioplasty and 
the restenosis rate in each stent group are shown in Ta-
ble II. The treatment strategies for recurrent restenosis 
are shown in Table III.
Follow-up
There were 13 cases (13/52 – 25%; age 52–77 years, 
8 men) of ≥ 70% recurrent ISR; all were neurologically 
asymptomatic. The mean time to second in-stent rest-
enosis was 26 months in the bare balloon group and 
23 months in the DEB group (p = NS). The prevalence 
of recurrent restenosis in the non-covered balloon group 
was 32% (6/19) vs. 23% (6/26) in the DEB group (p = NS).
Excluding 2 cases of balloon-mounted DES collapse 
(implanted in the way that they extended from the initial 
stent due to edge restenosis), there were no further rest-
enoses in the DES group in 20-month follow-up. Further 
cases of edge restenosis were treated with self-expand-
ing coronary stent. Three patients (3/52 – 5.8%) required 
a third intervention, and 1 patient with Takayasu arteritis 
required five interventions. 
Bilateral and high-grade stenosis were independent 
risk factors of restenosis (OR = 2.95, 95% CI: 1.87–4.64, 
p < 0.001 and OR = 1.9, 95% CI: 1.0–3.63, p = 0.049 re-
spectively). Initial Carotid Wallstent implantation was 
a risk factor of first and recurrent in-stent restenosis (vs. 
Table II. Numbers and percentages of stents used for initial angioplasty and restenosis rate in each stent group
Stent brand Initial CAS, N = 2637
n, % of the group
First > 50% restenosis, N = 95
n, % of the initial brand group
Second > 70% restenosis, N = 13
n, % of the initial brand group
Carotid Wallstent 968, 36.7 57, 5.89 8, 0.83 
Cristallo Ideale 546, 20.7 11, 2.01 1, 0.18 
Xact 381, 14.4 8, 2.10 1, 0.26 
Precise 322, 12.2 10, 3.10 1, 0.31 
Cguard 145, 5.5 3, 2.1 0
Acculink 97, 3.7 3, 3.09 2, 1.38 
Roadsaver 58, 2.2 2, 3.45 0
Vascuflex 50, 1.9 1, 2.00 0
NexStent 21, 0.8 0
Omni Link 13, 0.5 0
Exponent RX 8, 0.3 0
Palmaz 7, 0.3 0
Mer 5, 0.2 0
Smart 3, 0.1 0
Herculink 2, 0.1 0
Others 10, 0.4 0
Table III. Technical details of in-stent restenosis (ISR) endovascular treatment
Treated with First ISR Second ISR Third ISR
Uncovered balloon angioplasty 19/52* (36.5%)
DEB angioplasty 27/52 (50.9%) 4/13 (30.8%) 2/3 (66.7%)
Self-expanding carotid stent 6/52 (11.5%)
Balloon mounted coronary DES 8/13 (61.5%)
Self-expanding coronary DES 1/13 (7.7%) 1/3 (23.3%)
*52 cases of first ISR, one case of total occlusion is not included. DEB – drug-eluting balloon, DES – drug-eluting stent.
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combined group including all other stents, OR = 2.71, 
p < 0.001 and OR = 3.11, p = 0.032 respectively). Combin-
ing the three risk factors together (i.e. bilateral stenosis, 
high-grade stenosis and Carotid Wallstent implantation) 
significantly increases the odds ratios of a restenosis to 
6.19 (95% CI: 2.90–13.20, p < 000.1). Stent underexpan-
sion (n = 13) did not increase the risk of restenosis.
Discussion
Despite the limitations of DUS, associated with differ-
ent biomechanical characteristics of native and stented 
artery, it is the best tool for in-stent restenosis detection. 
There are at least several different cut-off criteria pro-
posed, based on PSV, end-diastolic velocity and PSV ratio. 
We decided to adopt the criteria of Lal et al. [13], as they 
showed a good correlation with angiological findings in 
detecting severe restenosis in our institution. Only 2 of 
53 arteries with suspected ≥ 70% DUS-detected reste-
nosis revealed borderline (40–70%) lumen narrowing in 
angiography.
Before the era of DEB, the carotid ISR was treated 
mainly with non-covered balloons with good immedi-
ate and long-term results. Our small sample of recurrent 
restenosis suggests that use of DEB does not significant-
ly prolong the time for the next intervention as compared 
with non-covered balloons.
There are data showing that restenosis may be symp-
tomatic and that it may be associated with significant 
risk of distal embolization during angioplasty for in-stent 
restenosis [6, 9, 10, 15]. This was a reason for the inter-
ventional approach to restenosis in our institution. Our 
results show that endovascular treatment of in-stent 
restenosis using neuroprotection is effective and safe, 
which also relates to patients treated for recurrent steno-
sis. The only case of periprocedural stroke was probably 
associated with mobilization of plaque fragments during 
catheter maneuvering and balloon inflation.
To date, there are no well-defined guidelines that 
establish the most effective approach for ISR treatment. 
While different endovascular strategies have been re-
ported, mainly with uncovered and covered balloons, 
none of them may be applied in each patient.
The main disadvantage of DEB use is the necessity of 
prolonged inflation for optimal drug delivery. Transient, 
balloon-related flow stoppage in the treated artery may 
provoke cerebral ischemia, especially in patients with co-
existing contralateral occlusion. In our DEB group there 
was a high (40.7%) percentage of neurological ischemic 
symptoms occurrence requiring shortening of the time 
of inflation to < 40 s. However, similar risk of, and time 
to, subsequent restenosis reoccurrence between uncov-
ered balloon and DEB groups may only be an accidental 
finding as there are no robust data comparing results of 
short vs. long inflation of DEB in restenosis treatment in 
the carotid territory. 
As we have shown, recurrent restenosis may be 
treated safely with secondary balloon angioplasty, or, 
in some selected cases, with balloon-mounted DES 
implantation. In 6 out of 8 cases of balloon-mounted 
DES implantation there was no further restenosis. In 
2 cases, edge DES implantation resulted in further stent 
deformation and artery occlusion in one, as described 
previously [11]. This is due to the fact that the coronary 
DES is prone to deformation in the segment of the ar-
tery that bends and kinks. This observation prompted 
us to introduce self-expanding drug-eluting coronary 
stent for patients with recurrent edge-stent resteno-
sis. Mechanical properties of this stent are similar to 
self-expanding carotid stents in terms of radial force 
and resistance to deformation. Edge stent restenosis 
may be provoked by mechanical repeating wall injury 
at the border between the stent edge and native vessel 
wall. The compliance mismatch of the stented segment 
and native artery wall provokes unnatural artery kink-
ing at the end of stent while neck movement leads in 
consequence to repeated local intimal irritation and in-
flammatory response. This phenomenon may be more 
pronounced with closed-cell design stents (CC). In fact, 
the comparison of CC and open-cell design stents (OC) 
indicates significantly increased stiffness in the former 
group [16]. We hypothesized that the CC stent may have 
higher rate of restenosis. In fact, this correlation was 
not found for the whole groups of stents (CC vs. OC); it 
was only demonstrated for the Carotid Wallstent. This 
phenomenon is difficult to explain, but there might be 
several mechanisms responsible for it:
Carotid Wallstent bending stiffness is similar to the 
majority of stents in our group, but its length change 
during implantation is definitely the greatest (–22% vs. 
–5.9% for Precise, –2.4% for Xact and +0.5% for Cris-
tallo Ideale) [16]. Furthermore, stent shortening during 
follow-up, as described in several case reports, may lead 
to partial plaque uncovering and accelerate restenosis. 
Gaudry et al. report 3 out of 12 restenoses associated 
with Carotid Wallstent shortening. Interestingly, lack of 
stent coverage of the common carotid artery was an in-
dependent restenosis risk factor [17]. Moreover, the Ca-
rotid Wallstent has the lowest radial force [16], reducing 
the chance of further stent expansion, and it was shown 
that at higher radial force, the stent has better chances 
of making the artery conform to its original shape [18]. 
Non-circular stent cross section may provoke flow dis-
turbances, increase in shear stress and in consequence 
stimulate neointima proliferation.
Another interesting finding is that the Carotid Wall-
stent is the only one made of unique cobalt-chromi-
um-iron-nickel-molybdenum alloy containing an en-
hanced radiopaque tantalum core, whereas all other 
stents from our group are made of Nitinol (nickel-titani-
um alloy). There are data suggesting that in some cases 
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in-stent restenosis may be influenced by metal allergy 
[19], including hypersensitivity to molybdenum [20]. The 
Carotid Wallstent also has the smallest free cell area in 
the CC group, 1.1 mm2; while for Xact it is 2.7 mm2 and 
≥ 4  mm2 for other stents. The higher density of metal 
mesh, with possible hypersensitivity to metal, may play 
a role in restenosis development.
The type of stent has not yet been investigated as 
a potential risk factor of restenosis. In most cases, this is 
because of a small sample of CAS and/or a single brand 
of stent used. The present study showed that Carot-
id Wallstent use strongly correlates with higher risk of 
restenosis. Although the Carotid Wallstent has not been 
shown as an in-stent restenosis risk factor so far, our 
findings are not isolated. Montelione et al. report 10 out 
of 12 symptomatic in-stent restenosis as occurred in the 
Carotid Wallstent [21].
It should be kept in mind that the difference in 
stent-dependent segmental elasticity may increase DUS 
velocities for CC as compared to OC stents and that may 
influence the restenosis rate overestimation in the for-
mer group. This was not the case in our study, as we 
confirmed all critical restenosis in angiography. Interest-
ingly, in both Acculink stents that developed critical rest-
enosis that was treated with POBA, recurrent restenosis 
occurred. The small size of the group did not allow for 
a statistical confirmation of this observation.
Severe ICA stenosis was recognized in our group of 
patients as a  restenosis risk factor, which is consistent 
with observations from the study of Gaudry et al. [17]. 
It has been found to be associated with higher plaque 
burden [22]. Bilateral ICA stenosis reflects considerable 
atherosclerosis progression and higher disease activity. 
This may explain the strong influence of bilateral ICA ste-
nosis on further in-stent restenosis. Veselka et al. found 
a significantly higher rate of restenosis in the group with 
bilateral carotid stenosis (vs. unilateral stenosis). This 
group was also characterized by a  higher rate of fol-
low-up death [23]. Another study showed contralateral 
carotid artery occlusion as a strong independent predic-
tor of in-stent restenosis [24].
On the other hand, ISR was treated successfully with 
DEB angioplasty with no third reoccurrence except for the 
patient with Takayasu disease.
Limitations
A  limitation of the study is that it is a one-center, 
non-randomized registry and our findings might not 
apply to other populations of patients. Another limita-
tion is possible stent selection bias as the use of stent 
type and brand was operator-dependent. Thus, some 
groups of stents are represented in small numbers and 
may not be able to provide sufficiently strong statisti-
cal data. 
Conclusions
Our findings suggest that balloon angioplasty may 
not be optimal for edge-stent restenosis as this proce-
dure does not eliminate the source of the problem that is 
local inflammation caused by repeating edge-stent me-
chanical injury. We believe that implantation of a self-ex-
panding DES may be considered in this specific clinical 
situation.
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